{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Malignancy+%28Lymphoma+and+CLL%29&page=45",
    "query": {
      "condition": "Lymphoid Malignancy (Lymphoma and CLL)",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Malignancy+%28Lymphoma+and+CLL%29&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Malignancy+%28Lymphoma+and+CLL%29&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T14:40:38.112Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03702231",
      "title": "Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Safety and Tolerability",
        "Compare SHINGRIX Vaccine Response Rates",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Small Lymphocytic Lymphoma (SLL)"
      ],
      "interventions": [
        {
          "name": "Zoster Vaccine Recombinant, Adjuvanted",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 116,
      "start_date": "2018-12-07",
      "completion_date": "2023-07-12",
      "has_results": true,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03702231"
    },
    {
      "nct_id": "NCT00364286",
      "title": "Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Dasatinib (BMS-354825)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 17,
      "start_date": "2006-08",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00364286"
    },
    {
      "nct_id": "NCT00014469",
      "title": "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "2000-12",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2013-03-07",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014469"
    },
    {
      "nct_id": "NCT04419519",
      "title": "Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Small Lymphocytic Lymphoma (SLL)"
      ],
      "interventions": [
        {
          "name": "Venetoclax monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax with anti CD20 monoclonal antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2020-05-13",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 9,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419519"
    },
    {
      "nct_id": "NCT01647971",
      "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma",
        "B-cell Lymphoma",
        "Waldenstrom's Macroglobulinemia",
        "Marginal Zone Lymphoma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Small Lymphocytic Lymphoma (SLL)",
        "Primary Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2012-07-19",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2022-11-21",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 8,
      "location_summary": "Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01647971"
    },
    {
      "nct_id": "NCT00058292",
      "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "yttrium Y 90 ibritumomab tiuxetan",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2000-04",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-06-01",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Rochester, Minnesota",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058292"
    },
    {
      "nct_id": "NCT01769222",
      "title": "Ipilimumab and Local Radiation for Selected Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Colon Cancer",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Melanoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Rectal Cancer",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Hairy Cell Leukemia",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "T-cell Large Granular Lymphocyte Leukemia",
        "Testicular Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2013-02",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01769222"
    },
    {
      "nct_id": "NCT00642031",
      "title": "Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancies",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Triciribine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prescient Therapeutics, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2006-08",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2016-08-09",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00642031"
    },
    {
      "nct_id": "NCT00466895",
      "title": "Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leslie Andritsos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2007-04",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00466895"
    },
    {
      "nct_id": "NCT00003356",
      "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 58,
      "start_date": "1997-11",
      "completion_date": "2002-05",
      "has_results": false,
      "last_update_posted_date": "2013-10-16",
      "last_synced_at": "2026-10-25T14:40:38.112Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003356"
    }
  ]
}